Presented by the Chao Family Comprehensive Cancer Center and Cambridge Healthtech Institute and held at the University of California, Irvine Student Center

A number of breakthrough technologies are being incorporated into novel diagnostics to detect a range of molecular and protein biomarkers.  The diagnostic methods applied will include PCR, microarrays, sequencing, proteomics, methylation, and mutation detection. This meeting will highlight the next generation of diagnostic platforms that encompass the latest trends in microfluidics, point-of-care technologies, in vivo sensing, and consumer-driven products.  A panel of experts will focus on translation to the medical community and the key to success in implementation.

Topics include:

• Microfluidic Technology and Business Trends
• Point-of-Care Diagnostics
• Nanotechnology Advances
• Innovation in Microfluidics
• In vivo Diagnostic Imaging
• Recent Approvals of Companion Diagnostics

Scientific Advisory Board:

• John C. Carrano, Ph.D., President, Carrano Consulting, LLC
• John J. Krolewski, M.D., Ph.D., Professor, Pathology & Laboratory Medicine, University of California, Irvine
• Young Jik Kwon, Ph.D., Associate Professor, Department of Pharmaceutical Sciences, Department of Chemical Engineering and Materials Science, University of California, Irvine
• Frank L. Meyskens, Jr., M.D., Director, Chao Family Cancer Center, University of California, Irvine
• Edward L. Nelson, M.D., FACP, Chief, Heme/Onc Division, Associate Professor, Medicine and of Molecular Biology & Biochemistry, University of California, Irvine
• Jennifer Prescher, Ph.D., Assistant Professor, Departments of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine
• Gregory A. Weiss, Ph.D., Professor, Departments of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine | Conference Chairman